PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-0.81%
Negative revenue growth while AVGO stands at 2.91%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-0.55%
Negative gross profit growth while AVGO is at 5.47%. Joel Greenblatt would examine cost competitiveness or demand decline.
-1.41%
Negative EBIT growth while AVGO is at 20.38%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-1.41%
Negative operating income growth while AVGO is at 20.38%. Joel Greenblatt would press for urgent turnaround measures.
-3.47%
Negative net income growth while AVGO stands at 4.08%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-5.13%
Negative EPS growth while AVGO is at 3.23%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-2.63%
Negative diluted EPS growth while AVGO is at 3.45%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
0.33%
Share count expansion well above AVGO's 0.49%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
0.16%
Diluted share reduction more than 1.5x AVGO's 0.47%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
-0.33%
Dividend reduction while AVGO stands at 10.07%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
-37.95%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-42.92%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
184.00%
10Y revenue/share CAGR under 50% of AVGO's 617.66%. Michael Burry would suspect a lasting competitive disadvantage.
139.27%
5Y revenue/share CAGR at 75-90% of AVGO's 155.11%. Bill Ackman would encourage strategies to match competitor’s pace.
53.31%
3Y revenue/share CAGR above 1.5x AVGO's 25.54%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
15658.45%
10Y OCF/share CAGR above 1.5x AVGO's 2655.74%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
230.39%
5Y OCF/share CAGR at 50-75% of AVGO's 345.86%. Martin Whitman would question if the firm lags in monetizing revenue effectively.
210.79%
3Y OCF/share CAGR above 1.5x AVGO's 85.64%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
515.64%
Net income/share CAGR at 75-90% of AVGO's 586.81%. Bill Ackman would press for strategic moves to boost long-term earnings.
511.88%
5Y net income/share CAGR above 1.5x AVGO's 148.15%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
74.39%
Positive short-term CAGR while AVGO is negative. John Neff would see a clear advantage in near-term profit trajectory.
322.99%
Below 50% of AVGO's 765.82%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
157.07%
5Y equity/share CAGR at 50-75% of AVGO's 218.15%. Martin Whitman would question a shortfall in capital accumulation vs. the competitor.
105.96%
Positive short-term equity growth while AVGO is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
90.49%
Below 50% of AVGO's 758.63%. Michael Burry worries the firm returns far less capital to shareholders over 5 years.
15.23%
Below 50% of AVGO's 105.36%. Michael Burry suspects the firm invests elsewhere or can’t match the competitor’s dividend policy.
15.09%
AR growth well above AVGO's 9.88%. Michael Burry fears inflated revenue or higher default risk in the near future.
15.22%
We show growth while AVGO is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
34.30%
Asset growth above 1.5x AVGO's 1.37%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
6.98%
Positive BV/share change while AVGO is negative. John Neff sees a clear edge over a competitor losing equity.
196.94%
Debt growth far above AVGO's 2.12%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
-0.41%
Our R&D shrinks while AVGO invests at 2.45%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
2.09%
We expand SG&A while AVGO cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.